Mclean, VANCT07301008Now EnrollingIRB Ready

Migraine Clinical Trial in Mclean, VA

Access cutting-edge migraine treatment through this phase 4 clinical trial at a research site in Mclean. Study-provided care at no cost to qualified participants.

Sponsored by Medstar Health Research Institute

Quick Self-Assessment

See if you qualify for this Mclean location

Preparing your pre-screening questions…

Expert Care in Mclean

Access migraine specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related migraine treatment provided free

Apply for This Mclean Location

Check if you qualify for this migraine clinical trial in Mclean, VA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Mclean

    Convenient for VA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Mclean site if eligible
  4. 4Begin participation

About This Migraine Study in Mclean

Single-center, open label, prospective study conducted at Medstar Georgetown Headache Center. Men and woman ≥ 18 years old that are diagnosed with migraine with or without aura for at least 1 year, who report a reliable migraine trigger. Acceptable triggers for the study will include exercise, alcohol (less than one drink per day for woman and less than two drinks per day for men), air travel that lasts no more than 12 hours, sexual activity, fasting that lasts no more than 24 hours, stress or stress let-down headache.

Sponsor: Medstar Health Research Institute

Who Can Participate

Inclusion Criteria

Patients with at least 1 year history of episodic migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders-3 (ICHD-3)
Men and women ≥ 18 years old .
Average of 2-8 migraine attacks of moderate or severe intensity per month within the last 3 months prior to the screening visit
Headache/migraine onset before age 50 years
Migraine attacks, on average, lasting 4-72 hours if untreated
At least 48 hours between migraine attacks
Ability to distinguish migraine attacks from tension or cluster headaches
Particpants on SOC treatment should be on stable regimen for at least 3 months prior to enrollment and should not change their regimen during the course of the study
Participant may have been on treatment with Botox or mAbs for the last 6 months
Participants experience migraine ≥75% of the time following exposure to a trigger during the run-in period. Acceptable triggers include exercise, alcohol ( less than one drink per day for woman and less than two drinks per day for men), air travel that lasts no more than 12 hours, sexual activity, fasting that lasts no more than 24 hours, stress or weekend/ let-down

Exclusion Criteria

Using gepants as preventive treatment (atogepant once daily (QD) or rimegepant every other day (EOD)), or using zavegepant or ubrogepant as an acute treatment
History of use of narcotic or barbiturate containing medications, including opioids (e.g., morphine, codeine, oxycodone, and hydrocodone) on ≥5 days per month on a regular basis for ≥3 months prior to screening
Current evidence of uncontrolled, unstable, or recently diagnosed cardiovascular disease, uncontrolled hypertension, or uncontrolled diabetes.
Current diagnosis of major depressive disorder requiring treatment with atypical antipsychotics, schizophrenia, bipolar disorder, or borderline personality disorder.
Women must not be pregnant, lactating or breastfeeding

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Mclean?

Yes, this clinical trial (NCT07301008) has an active research site in Mclean, VA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Migraine Treatment Options in Mclean, VA

If you're searching for migraine treatment options in Mclean, VA, this clinical trial (NCT07301008) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Mclean research site is actively enrolling participants for this phase 4 clinical trial. You'll receive care from experienced migraine specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all migraine clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Mclean, VA

See all heart attack clinical trials recruiting in Mclean — not just this study.

Browse Heart Attack Trials in Mclean →

Browse More Trials by Condition

Heart Attack TrialsMigraine TrialsRheumatoid Arthritis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Mclean?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Mclean, VA